

# FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort.

Mathieu Hatt, Mohamed Majdoub, Martin Vallières, Florent Tixier, Catherine Cheze Le Rest, David Groheux, Elif Hindé, Antoine Martineau, Olivier Pradier, Roland Hustinx, et al.

## ▶ To cite this version:

Mathieu Hatt, Mohamed Majdoub, Martin Vallières, Florent Tixier, Catherine Cheze Le Rest, et al.. FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort.: FDG-PET heterogeneity and volume. Journal of Nuclear Medicine, 2014, pp.20. inserm-01096308

# HAL Id: inserm-01096308 https://inserm.hal.science/inserm-01096308

Submitted on 17 Dec 2014

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort

Mathieu Hatt<sup>1</sup>, Mohamed Majdoub<sup>1\*</sup>, Martin Vallières<sup>2\*</sup>, Florent Tixier<sup>1,3</sup>, Catherine Cheze Le Rest<sup>3,1</sup>, David Groheux<sup>4</sup>, Elif Hindié<sup>4</sup>, Antoine Martineau<sup>4</sup>, Olivier Pradier<sup>1,5</sup>, Roland Hustinx<sup>6</sup>, Remy Perdrisot<sup>3</sup>, Remy Guillevin<sup>7</sup>, Issam El Naqa<sup>2</sup>, Dimitris Visvikis<sup>1</sup>

\* Equally contributed

<sup>1</sup> INSERM, UMR 1101 LaTIM, Brest, France.
<sup>2</sup> Department of Oncology, McGill University, Montreal, Canada.
<sup>3</sup> Nuclear Medicine, CHU Milétrie, Poitiers, France
<sup>4</sup>Nuclear Medicine, CHU Saint Louis, Paris, France.
<sup>5</sup>Radiotherapy, CHRU Morvan, Brest, France.
<sup>6</sup>Nuclear Medicine, CHU Liège, Belgium.
<sup>7</sup>Radiology, CHU Milétrie, Poitiers, France.

## Running title: FDG-PET heterogeneity and volume

Corresponding author: M. Hatt, INSERM, UMR 1101,LaTIM CHRU Morvan, 2avenue Foch 29609, Brest, France Tel: +33(0)2.98.01.81.11 Fax: +33(0)2.98.01.81.24 E-mail: hatt@univ-brest.fr

## Wordcount: 4925

Disclosure of Conflicts of Interest: No conflicts of interest.

**Funding**: This work has received a French government support granted to the CominLabs excellence laboratory and managed by the National Research Agency in the "Investing for the Future" program under reference ANR-10-LABX-07-01.

### ABSTRACT

Intra-tumor uptake heterogeneity in <sup>18</sup>F-FDGPET has been associated with patient treatment outcomes in several cancer types. Textural features (TF) analysis is apromising method for its quantification. An open issue associated with the use of TF for the quantification of intratumoral heterogeneity concerns its added contribution and dependence on the metabolically active tumor volume (MATV), which has already been shown as a significant predictive and prognostic parameter.Our objective was to address this question using a largercohort of patients covering different cancer types.

**Methods**: Asingle database of 555 pre-treatment <sup>18</sup>F-FDG PET images (breast, cervix, esophageal, head&neck andlung cancer tumors) was assembled. Fourrobust and reproducibleTF-derived parameters wereconsidered. The issues associated with the calculation of TF using co-occurrence matrices(such as the quantization and spatial directionality relationships) werealso investigated. The relationship betweenthese features and MATV, as well as among the features themselves was investigated using Spearman rank coefficients, for different volume ranges. The complementary prognostic value of MATV and TF was assessed through multivariate Cox analysis in the esophageal and NSCLC cohorts.

**Results**: A large range of MATVs was included in the population considered (3-415 cm<sup>3</sup>, mean=35, median=19, SD=50). The correlation between MATV and TF varied greatly depending on the MATVs, with reduced correlation for increasing volumes. These findings were reproducible across the different cancer types. The quantization and the calculation method both had an impact on the correlation.Volume and heterogeneity were independent prognostic factors (*P*=0.0053 and 0.0093respectively) along with stage (*P*=0.002) in NSCLC, but in the esophageal

tumors, volume and heterogeneity had less complementary value due to smaller overall volumes.

**Conclusion**: Our results suggest that heterogeneity quantification and volumemay provide valuable complementary informationforvolumesabove 10cm<sup>3</sup>, although the complementary information increases substantially with larger volumes.

**Keywords**: <sup>18</sup>FDG-PET/CT, heterogeneity, textural features, metabolically active tumor volume, prognosis.

<sup>18</sup>F-FDG Positron Emission Tomography/Computed Tomography (PET/CT) is a powerfultoolfor diagnosis and staging inoncology (1). lts use intherapy assessment(2,3)isincreasing. Within this context more and more emphasis is being given to image-derived indices (4). On the one hand, features extracted from PET images, including metabolically active tumor volume (MATV), mean standardized uptake value (SUV<sub>mean</sub>) and total lesion glycolysis (TLG) have provided potentially higher prognostic value than standard maximum SUV (SUV<sub>max</sub>) in various cancer types(5).On the other hand, more recently the heterogeneity of <sup>18</sup>F-FDG uptakes within tumorshas been associated with treatment failure (4,6-8). Proposed approaches for the assessment of intra-tumor activity distribution heterogeneity includevisual evaluation (9), SUV coefficient of variation (SUV<sub>COV</sub>) (10), area under the curve of the cumulative histogram (CH<sub>AUC</sub>) (11), fractals(12) or textural features(TF)analysis (10,13).The lattercan provide а number of parametersquantifyingtumor heterogeneity at the scales of voxels or groups of voxels. A recent study, based on the use of one of these parameters (local entropy calculated from co-occurrence matrices) has suggested that a minimum MATV of 45cm<sup>3</sup> is required to provide an estimate of heterogeneity independent of MATV confounding effects(14). However, this studyinvestigated a single heterogeneity parameter, ina single cancer type, and used an image guantization schemewith>150 grey levels. Another recent study investigating the relationship between MATV and TF(15)has included a relatively small number of tumors (including patients who already had distant metastases) and cancer types, without explicitly reporting on the lesion sizes considered or making conclusions regarding the minimum tumor volume that should be considered. In addition, this study used Pearson correlation to

testlinear relationship between MATV and TF, which would missnon-linear trendsthat may exist between these parameters.

To our knowledge, the potential interactionbetween MATV and TF has not been previously considered within the context of patient outcome prognosis.

This study was therefore designed to investigate in detail, and across a large number of primary tumors and cancer types, the relationship between tumor MATV and derived heterogeneity measurements using TF, in order (a) to determine whether a minimum MATV should be considered in such analyses and (b) if tumor heterogeneity quantified through TF could provide complementary prognostic value relative to MATV.

### MATERIALS AND METHODS

#### FDG PET images

Severalpatient cohorts wereretrospectively collectedin a dataset of 555<sup>18</sup>F-FDG PET baseline images of different primary locally advanced tumors, excluding patients with distant metastases because they usually have a very different prognosis and treatment management. In all cohorts, patients were selected as consecutive patients withan <sup>18</sup>F-FDG PET/CT scan at diagnosis prior to any treatment.

The resulting datasetconsisted of158 breasttumors with three different subtypes (luminal, her2+/ER-, triple negative), 45 cervixtumors, 112 esophageal tumors, 139 head and neck (H&N) tumors, and 101 non-small cell lung cancer (NSCLC) tumors (Fig. 1).These tumor entities were chosen because they have often been considered in the literature for studying FDG uptake heterogeneity. They have a wide range of tumor size, significant FDG uptake, and a high rate of treatment failures. Each cohort for a given cancer site came from one clinical center except H&N tumors that

involved two different University Hospitals (Supplemental Table 1). Within each cohort, all acquisitions followed corresponding institutional protocols. All cohorts except the 66 H&N tumors from McGillwere acquired usingthe same acquisition settings and protocols: a Philips GEMINI PET/CT scanner, CT-based attenuation correction, reconstruction with 3D Row-Action Maximum Likelihood Algorithm with 4x4x4mm<sup>3</sup> voxels and 5mm full-width-at-half-maximum Gaussian post-filtering, 6-hour fasting period, 3D whole-body acquisition performed60 min after injection of <sup>18</sup>F-FDG, and SUV normalized using body weight. The acquisitions for the 66 H&N tumors from McGill shared the same settings expect for the scanner model (a GE Discovery ST) and Ordered-Subset Expectation Maximization reconstruction (3.52×3.52×3.27mm<sup>3</sup> voxels) without post-filtering.

Only primary tumors (not lymph nodes) with MATVs >3cm<sup>3</sup>(which, assuming a spherical shape, corresponds to ~1.8cm diameter) were included due to thelimitations of PET imaging to characterizetracer distribution within smallertumors because of its limited spatial resolution and resulting partial volume effects (PVE).

The institutional review boards of each involved group in this work approved this retrospective study and the requirement to obtain informed consent was waived.

## Image Analysis

MATVswere firstdelineatedusing the Fuzzy Locally Adaptive Bayesian (FLAB) algorithm(16), which has been previously validated for accuracy and robustness using simulated and clinical datasets, including homogeneous and heterogeneous MATVs(17,18). FLAB was used with two or three classes in order to adequately cover

the entire MATV, including low uptake areas. The H&N tumors from McGill were manually delineated by an experienced radiation oncologist on fused PET/CT images as part of their radiotherapy treatment planning.

The differences in scanner, reconstruction and delineation between the H&N McGill dataset and the other cohorts were taken into account by only considering features that were shown to be the most robust with respect to PVEand segmentation (19) or reconstruction settings (20), as well as test-retest reproducibility (21).

Consequently, the present analysis included fourTFs, which have been previously shown to have a predictive and prognostic value in different cancer types. The two local TFscalculated using co-occurrence matrices(13)were entropy (E)and dissimilarity (D). D and E were calculated according to two different methods: 1) using 13 matrices, one for each spatial direction, followed by averaging the values calculated separately in each matrix, and2) using only one matrix taking into account all 13 directions simultaneously without an averaging step. From a conceptual point of view, the second method is more accurate, as it fully describes the 3D co-occurrence properties within the volume. The first method results in taking an average from fewer co-occurrence measurements, thus information could be lost and the complexity of the distribution of grey levels may not be optimally captured. On the other hand, averaging could artificially reduce the effect of the residual noise from the quantization process. The parameters related to the first method (averaging 13 matrices) will be denoted as E<sup>13</sup> and D<sup>13</sup>, whereas the parameters from the second method (1 matrix) will be denoted as  $E^1$  and  $D^1$ .

RegionalTFs calculated using size-zone matrices (13)were high intensity large area emphasis (HILAE) and zone percentage (ZP).

Other TFs were not included in the present analysis because of high correlation with D and/or E (correlation>0.8), or previously shown poor reproducibility/robustness (19–21) (supplemental Table 2).

Although an optimal quantization of 64 grey levels was identified in our previous work concerning the reproducibility(19), we also investigated the impact of the quantization pre-processing step by considering values from 4 to 256.

Finally, SUV<sub>max</sub>, SUV<sub>mean</sub>, and SUV<sub>COV</sub>were includedfor comparison purposes.

#### Statistical Analysis

Statistical analyses were performed using Medcalc<sup>™</sup> (MedCalc Software, Belgium). Spearman rank correlation (*rs*) was used to study relationships between parameters, since such relationships are non-linear and all these parameters are frequently not normally distributed. In order to assess the potential complementarity and/or additional clinical value of MATV and derived heterogeneity parameters, a survival analysis was performed in theesophageal and NSCLC cohorts for which overall survival (OS), follow-up and other clinical data were available (Supplemental Tables3 and 4), which was not the case for the other cohorts. Association with OS was assessed using univariate Cox proportional hazard regression including features as continuous variables (*i.e.* no dichotomization). Correction for multiple testing was performed using the false discovery rate Benjamini-Hochberg step-up procedure. It consists in declaring positive discoveries at level  $\alpha$  (here  $\alpha$ =0.05), among the *k*=1...K tested variables ordered according to their p-values p in increasing order, those ranked above the one satisfying the condition  $p(k) \leq \frac{k}{\kappa} \times \alpha$  (22). After univariate analysis, a stepwise multivariate Cox analysis(significant variables are entered sequentially, then removed if they become non-significant) was performed to identify

independent prognostic factors. Kaplan-Meier survival curves (with optimal cut-off values determined through ROC curves analysis) were subsequently used to assess the prognostic value of previously identified independent factors. Median survival, percentage of deaths in each group and hazard ratios(HR) were reported for each risk factor separately and for their combination, in order to quantify anyimprovedpatient stratification.

## RESULTS

### **Correlation betweenparameters**

To avoid confusion, absolute *rs* values are reported, although correlation direction results can be found in figure 2. Threeimportant observations can be emphasized.

First, significant detailsregarding the grey-levels distribution are lost when using a quantization <32 (Fig. 3), and the quantization had an important impact on the correlation between volume and E<sup>1</sup>, decreasing from almost 1 for a quantization of 256, to <0.6 for quantization<64. Correlation with MATV was much lower for E<sup>1</sup>compared to E<sup>13</sup>, except for quantization <16. In contrast, dissimilarity (either D<sup>1</sup> or D<sup>13</sup>) was insensitive to the quantization value (*rs*~0.8) and there was no difference between D<sup>1</sup> and D<sup>13</sup>. The correlation ofHILAE and ZP withMATV was very sensitive to the quantization, although contrary to entropy, *rs* increased from <0.5 to >0.8 with decreasing quantization (Fig. 3). For quantization=32, the correlation with volume was >0.75 and <0.85 for all TFs except E<sup>1</sup> (0.3), whereas withquantization=64 there was a wider range (*rs*<0.2 for HILAE to *rs*~1 for E<sup>13</sup>), and several TFs had a correlation <0.7, suggesting a higher potential of complementary information with respect to MATV for 64 than 32. Quantization=64 was also previously shown to provide the highest TFs' reproducibility (21) and robustness(19).A quantization into 64 grey-

levels wasthus considered for the rest of the analysis, as it represents the best compromise between sufficient sampling of voxel SUVs, preservation of original intensities information, andpotential complementary information with respect to MATV.

Secondly, significant correlations were found amongst almost all features considered. In addition, MATV correlated with those features, as well as with SUV<sub>max</sub> and SUV<sub>mean</sub> (Fig. 2). The correlation between the co-occurrence matrix-derived features themselves and their respective correlation with MATV were sensitive to theuse of asingle matrix compared to averaging 13 directional matrices. This was particularly true for entropy. The correlation between D<sup>13</sup> and E<sup>13</sup> was 0.76, whereas the correlation between D<sup>1</sup> and E<sup>1</sup>was 0.18. Correlation of D<sup>13</sup> and E<sup>13</sup> with MATV was 0.80 and 0.96, whereas it was 0.82 and 0.56 for D<sup>1</sup> and E<sup>1</sup>respectively (Fig.2).

Thirdly, correlation between  $D^1$ ,  $E^1$ , ZP, and HILAE with MATV ranged from 0.17 to 0.96, suggesting that a substantial amount of complementary information with respect to MATV may be found in some of these heterogeneity quantification features, similarly to SUV measurements which exhibited correlations of 0.31 to 0.42.

Figures 4 and 5 provide visual representations of the distributions of TFs with respect to MATV.Supplemental figures 1-4 provide similar graphsfor each cancer type, for other TFs and quantization values. The difference between  $E^{13}$  and  $E^{1}$  was important (Fig.4A-B), the calculation using only one matrix leading to a much tighter distribution with a smaller range (5.6-8 for  $E^{1}vs$ . 3.9-7.3  $E^{13}$ ) of higher values (7.1±0.4 *vs*. 5.7±0.8), and with substantially lower correlation with volume (0.56*vs*. 0.96). The

difference between  $D^{13}$  and  $D^{1}$  (Fig.4C-D) was less important but nonetheless led also to a tighter distribution for  $D^{1}$  with a smaller range (3.5-24.1 *vs.* 0.9-30.5) of higher values (12.6±3.8 *vs.* 10.7±3.7) but with a similar correlation with MATV (0.82*vs.* 0.80).

By restricting the analysis to larger tumor volumes (from  $\ge 10 \text{cm}^3$  to  $\ge 60 \text{cm}^3 \text{using}$ 5cm<sup>3</sup> steps), it was found thatthe correlation between TFs and MATV tended to decrease substantially with ranges of increasing volumes (Fig. 6). This was observed for all TFs but was especially true for entropy. The only exception to this observation was HILAE since its correlation with MATV was low even when considering the entire dataset.E<sup>13</sup>correlation with MATVdropped from 0.96 when considering the entire range of volumes, to <0.3 when considering only tumors >60cm<sup>3</sup>. E<sup>1</sup> dropped to <0.25 for volumes >10cm<sup>3</sup>. Similar observations were made for D<sup>13</sup> with rs>0.8 when considering all tumors, dropping <0.6 in tumors >15cm<sup>3</sup>. Although the overall correlation of D<sup>1</sup>with MATV was slightly higher than for D<sup>13</sup>, it was also more rapidly reduced with increasing MATV (Fig.6). The same analysis for ZP led to similar observations, witha reduced correlation with increasing MATV when considering larger tumors, from 0.68for all tumors to 0.5 for those >15cm<sup>3</sup>.

The relationships between MATV and TFs were similar across the different tumor types, although measured correlations varied: cervix tumors included mostly large tumors (MATV>20cm<sup>3</sup>), whereas the other tumor types included a larger number of tumors with MATV<10cm<sup>3</sup> (Fig.1). The resulting correlation between E<sup>1</sup> and MATV was not significant for cervix cancer tumors (*rs*<0.003, *P*>0.9), whereas it wasfor esophageal, NSCLC, H&N, and breast tumors (*rs*=0.80, 0.39, 0.35, and 0.74)

respectively). For dissimilarity ( $D^1$ ) and ZP, smaller differences were observed, with *rs* from 0.73 and 0.63 (cervix) to 0.93 and 0.83 (NSCLC) for D1 and ZP respectively. HILAE correlations with MATV were <0.2 for all tumor types.

#### Survival prognosis in esophageal and NSCLC cohorts

In the esophageal cohort, median OS was17.0 months (range 1.0-71.0, mean 22.0), with 44 patients still alive at last follow-up. The trend for MATV did not reach statistical significance (p=0.0315) and none of the variableswere prognostic factorsexcept D<sup>1</sup> (p=0.0016) (Table 1), therefore no multivariate analysis was performed. However, if dichotomized with optimal cut-off values in the K-M analysis, both D<sup>1</sup> (HR 1.92, p=0.0052) and MATV (HR 1.66, p=0.0375) could differentiate survival curves(Fig.7A). Adding volume and heterogeneity increased HR to 2.02 (p=0.0024, 95% CI 1.22-3.34) with 23months (*N*=64) *vs*.10months (*N*=48) median OS (supplemental table 5, Fig. 7A).

In the NSLC cohort, medianOS was 18.4 months (range 1.1-57.4, mean 27.4), with 39 patients still alive at last follow-up. In the univariate analysis, all variables were significantly associated with OS, expect age, histology, smoking history and SUV<sub>max</sub> (Table 1).The multivariate analysis retained clinical stage (P=0.0018), MATV (P=0.0053) and heterogeneity (E<sup>1</sup>, P=0.0093) as independent prognostic factors.MATV allowed for the highest differentiation (HR=2.8), whereas stage and heterogeneity led to lower HRs (2.3 and 2.1 respectively). Adding stage to MATV did not increase stratifying power (HR=2.84), whereas adding heterogeneity increased HR to 3.55, with 49months*vs*. 9.1months median OS. The addition of the three led to

the highest HR of 3.81(supplemental table 6, Fig. 7B). Survival curves were also evaluated according to a 3-valued score (MATV<35cm<sup>3</sup> AND E<sup>1</sup><7.35, MATV>35cm<sup>3</sup> OR E<sup>1</sup><7.35, and MATV>35cm<sup>3</sup> AND E<sup>1</sup>>7.35), leading to survival curves with median OS of 49, 20 and 9 months (p<0.0001, HRs of 1.8 and 4.3) (supplemental Fig. 5B, Fig. 7C), highlighting the higher complementary value of heterogeneity and volume in this cohort.

#### DISCUSSION

There is an increasing interest in the use of PETimagetextural featuresforquantification of intra-tumorheterogeneity(4,6). Few studies investigated the relationships between tumor volume and TFs(15,19,23).

Most studies using textural features considered volumes>3-5cm<sup>3</sup>, assuming that PET could not characterize heterogeneity on smaller volumes due to its limited spatial resolution. A recent theoretical analysis suggested that volumes>45cm<sup>3</sup> should be consideredto avoid volume related confounding effects(14). However, thisanalysisconsidered a single parameter (entropy), calculated on 2D co-occurrence spatial directions followed matricesover 2 by averaging, and using а quantizationvalue >150 (14).

In this work, we addressed the question of the minimum functional volume that could be considered and investigated the potential complementary prognostic value between volume and heterogeneity.We investigated the influence of the quantization pre-processing and of thetextural featurescalculation methodology, investigating more thoroughly the relationships between heterogeneity and functional volume in a substantially larger tumors' database, covering large tumor volume ranges and

different cancer types.Considering a patient cohort with variable cancer types and complementary volume ranges allowed providing a better picture of the relationship between the measured feature and its corresponding volume.

Our results partly confirm those of recent studies. Indeed, severaltextural featureswere found to be highly correlated with the volumefrom which they were calculated. In addition, high correlations were found between most of these parameters. We observed differences in the heterogeneity-volume distributions as a function oftumor type, although these differences can be explained by differences in volumeranges for each cancer patient cohort, rather than the histology or heterogeneity specific to each tumor type. For instance, the distribution of textural features with respect to volume in the cervix tumors was significantly different than the others because it included only large tumors (>20cm<sup>3</sup>) relative to the other patient cohorts considered that also included smaller tumor volumes.

Our results emphasize that(i) the relationship and the level of correlation is not the same for all features, (ii) the level of correlation tends to decrease substantially when consideringlargertumor volumes, (iii) the calculation method and the quantization step both have an impact on the relationshipand level of correlation between volume and the feature, and (iv) volume and heterogeneity can have complementary prognostic value: in the NSCLC cohort, heterogeneity and volumewere identified as independent prognostic factors and hazard ratios were shown to increase from <2.9 to >3.8 when adding these risk factors for patient stratification. Although multivariate analysis could not be performed in the esophageal cohort, combining heterogeneity with volume led to an increased although non-statistically significant different stratification. NSCLC tumor volumes were much larger than esophageal ones

 $(58\pm77$  cm<sup>3</sup>, median 34, range 3-415 *vs.*  $25\pm27$  cm<sup>3</sup>, median 15, range 3-140), which is likely why heterogeneity and volume had higher complementary prognostic values in NSCLC.

When considered together, these results point to the potential added prognostic value of tumor heterogeneity quantified with textural feature, although regarding Kaplan-Meier curves, cut-off values found with ROC analysis are probably over-fitted and specific to the data, and thus validation in independent cohorts will be required.

The guasi-linear relationship between entropy (either  $E^1$  or  $E^{13}$ ) and volume in the range3-10cm<sup>3</sup> (*rs*>0.9, Fig. 4) suggests that entropyfor volumes<10cm<sup>3</sup> cannot provide complementary information. However, when choosing appropriate quantization and co-occurrence matrix calculation, the correlation between volume and entropy for volumes in the range 10-50cm<sup>3</sup> was much lower. The minimal volume to consider may therefore be closer to 10cm<sup>3</sup> than 45cm<sup>3</sup>, a value previously suggested based on calculations carried out after a quantization into >150 grey-levels and using several co-occurrence matrices followed by averaging(14). In addition, for other TFs not considered in that last study, the correlation was weaker, even for volumes between 3 and 10cm<sup>3</sup>. It was only 0.4 and 0.6 for D<sup>13</sup> and D<sup>1</sup> respectively, and 0.3 and 0.2 for ZP and HILAE. Therefore, instead of excluding patients with volumes below the proposed 10cm<sup>3</sup> threshold from such analysis, we rather recommend to report the correlation between volume and heterogeneity and highlight their complementary value as tumor volumes increase. Indeed, the correlation with volume substantially for all textural features when considering decreased larger volumes.Larger tumors are known to exhibit higher hypoxia, necrosis or anatomical and physiological complexity at the microscopic and macroscopic scales, which logically translates to higher FDG uptake spatial distribution complexity and consequentlyassociated heterogeneity quantification. A significant correlation between quantified heterogeneity (viaany method) and its corresponding volume is therefore to be expected in a standard cohort of patients covering a large range of tumor sizes. Prospective clinical studies with optimized pre-defined imageacquisition settings and heterogeneity analysis protocols, as well as experimental studies demonstrating that tumor properties on a scale comparable with the PET resolution can actually lead to identifiable image textural features could benefit from the results of the present study and should now be conducted.

One important aspect of this study is that the 555 PET images in our databasecame from six cohorts acquired in differentcenters, albeit with certain homogeneity in acquisition parameters (same scanner, reconstruction algorithm, voxel size), except for one. This variability was handledby restricting the analysis to robust features only, as to minimize the associated impact. Indeed, excluding the H&N cohort with a different imaging protocol did not change the results. On the other hand, the inclusion of a small number of heterogeneity quantification metrics may be considered as a limitation. However, the four textural features includedhave been previously shown to be the most reproducible and robust amongst those shown to have a predictive and prognostic value in different cancer types. We also restricted the prognosis analysis to the esophageal and NSCLC cohorts because clinical and survival data for the other cohorts were not available forenough patients to allow formultivariate analysis.

### CONCLUSIONS

Most of textural features considered to quantify intra-tumor heterogeneity were found to be significantly correlated with tumor volume. However, our detailed analysis also

suggests that heterogeneity quantification through textural features may potentially provide valuable clinical complementary information in addition to functional volume, especially for tumors above 10cm<sup>3</sup>, with increasing complementary prognostic value for larger volumes. In 112 esophageal patients, heterogeneity was found to have some prognostic value that was not significantly improved when combined with volume, whereas in a cohort of 101 NSCLC patients, heterogeneity, volume and stage were independent prognostic factorsthat allowedincreased stratification of patients when combined.

## References

1. Krause BJ, Schwarzenbock S, Souvatzoglou M. FDG PET and PET/CT. *Recent Results Cancer Res.* 2013;187:351-69.

2. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. *J Nucl Med.* 2009;50 Suppl 1:122S-50S.

3. Herrmann K, Benz MR, Krause BJ, Pomykala KL, Buck AK, Czernin J. (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go. *Q J Nucl Med Mol Imaging*. 2011;55:620-32.

4. Visvikis D, Hatt M, Tixier F, Cheze Le Rest C. The age of reason for FDG PET image-derived indices. *Eur J Nucl Med Mol Imaging*. 2012;39:1670-2.

5. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. *Eur J Nucl Med Mol Imaging*. 2013;40:290-301.

6. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. *Eur J Cancer.* 2012;48:441-6.

7. Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. *Eur J Nucl Med Mol Imaging*. 2013;40:133-40.

8. Davnall F, Yip CS, Ljungqvist G, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? *Insights Imaging*. 2012;3:573-89.

9. Miller TR, Pinkus E, Dehdashti F, Grigsby PW. Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. *J Nucl Med*. 2003;44:192-7.

10. El Naqa I, Grigsby P, Apte A, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. *Pattern Recognit.* 2009;42:1162-1171.

11. Van Velden FH, Cheebsumon P, Yaqub M, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. *Eur J Nucl Med Mol Imaging*. 2011;38:1636-47.

12. Miwa K, Inubushi M, Wagatsuma K, et al. FDG uptake heterogeneity evaluated by fractal analysis improves the differential diagnosis of pulmonary nodules. *Eur J Radiol.* 2014;83:715-719.

13. Tixier F, Le Rest CC, Hatt M, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. *J Nucl Med*. 2011;52:369-78.

14. Brooks FJ, Grigsby PW. The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake. *J Nucl Med.* 2014;55:37-42.

15. Orlhac F, Soussan M, Maisonobe J-A, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. *J Nucl Med*. 2014;55:414-422.

16. Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D. A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. *IEEE Trans Med Imaging*. 2009;28:881-93.

17. Hatt M, Cheze le Rest C, Descourt P, et al. Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. *Int J Radiat Oncol Biol Phys.* 2010;77:301-8.

18. Hatt M, Cheze-le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D. Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. *J Nucl Med.* 2011;52:1690-7.

19. Hatt M, Tixier F, Cheze Le Rest C, Pradier O, Visvikis D. Robustness of intratumour <sup>18</sup>F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. *Eur J Nucl Med Mol Imaging*. 2013;40:1662-1671.

20. Galavis PE, Hollensen C, Jallow N, Paliwal B, Jeraj R. Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters. *Acta Oncol.* 2010;49:1012-6.

21. Tixier F, Hatt M, Le Rest CC, Le Pogam A, Corcos L, Visvikis D. Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET. *J Nucl Med.* 2012;53:693-700.

22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: apractical and powerful approach to multiple testing. *J R Stat Soc B*. 1995;57:289-300.

23. Willaime JMY, Turkheimer FE, Kenny LM, Aboagye EO. Quantification of intratumour cell proliferation heterogeneity using imaging descriptors of 18F fluorothymidine-positron emission tomography. *Phys Med Biol.* 2013;58:187-203.

Table 1. Prognostic value for OS in the NSCLC and esophagealcohorts assessed
using Cox regression for univariate and multivariate analysis

		Esophageal	NSCLC			
Parameters		p-value Univariate		alue Multivariate		
	Surgery	0.3654	0.0084	NRM		
	Age	0.1861	0.0441 <sup>¥</sup>	-		
Clinical	Sex	0.1795	0.0227	NRM		
	Smoker	0.4511	0.8997	-		
	Histology	0.2154	0.3041	-		
	Stage	0.0391 <sup>¥</sup>	0.0003	0.0018		
	MATV	0.0315 <sup>¥</sup>	0.0008	0.0053		
Volume and SUV	SUV <sub>max</sub>	0.2781	0.0599	-		
	${\sf SUV}_{\sf mean}$	0.6008	0.0256	NRM		
Heterogeneity (TF)	D <sup>13</sup>	0.0405 <sup>¥</sup>	0.0046	NRM		
	D <sup>1</sup>	0.0016	0.0027	NRM		
	E <sup>13</sup>	0.1087	0.0002	NRM		
	E <sup>1</sup>	0.3922	0.0287	0.0093		
	HILAE	0.2596	0.0132	NRM		
	ZP	0.4391	0.0005	NRM		

NRM: not retained in the model <sup>\*</sup>: Not significant after correction for multiple testing






Figure 1

	<b>D</b> <sup>13</sup>	D1	E <sup>13</sup>	E1	HILAE	ZP	ΜΑΤΥ	SUV <sub>max</sub>	SUV <sub>mean</sub>	SUV <sub>cov</sub>
D <sup>13</sup>	1									
D1	0,92 <0,0001	1								
E <sup>13</sup>	-0,76 <0,0001	-0,81 <0,0001	1							
E1	-0,40 <0,0001	-0,18 <0,0001	0,82 <0,0001	1						
HILAE	0,05 0,4	0,12 0,001	0,23 <0,0001	0,44 <0,0001	1					
ZP	0,72 <0,0001	0,84 <0,0001	-0,64 <0,0001	-0,06 0,2	-0,10 0,02	1				
MATV	-0,80 <0,0001	-0,82 <0,0001	0,96 <0,0001	0,56 <0,0001	0,17 <0,0001	-0,68 <0,0001	1			
SUV <sub>max</sub>	-0,29 <0,0001	-0,35 <0,0001	0,38 <0,0001	0,31 <0,0001	0,28 <0,0001	-0,32 <0,0001	0,42 <0,0001	1		
SUV <sub>mean</sub>	-0,11 0,027	-0,13 0,0033	0,38 <0,0001	0,47 <0,0001	0,40 <0,0001	-0,13 0,0086	0,31 <0,0001	0,89 <0,0001	1	
SUV <sub>cov</sub>	0,16 0,0006	-0,19 0,0001	-0,05 0,26	-0,19 0,0001	0,07 0,15	-0,30 <0,0001	0,08 0,084	0,30 <0,0001	0,07 0,17	1


Figure 2












В



А





Figure 4



A

Figure 5





Figure 6



С




Figure 7

## **Figure captions**

Figure 1. MATV distribution in each cancer site.

**Figure 2.**Illustration of quantization (A) and impact on the correlation between TF and MATV (B).

**Figure 3.** Spearman rank correlationsbetweenparameters(555 tumors). Red: [0.8,1.0] orange: [0.6,0.8[, green: [0.3,0.6[, violet: [0.1,0.3[ and grey: [0.0,0.1].

**Figure 4.** Distributions of E<sup>1</sup> (A), E<sup>13</sup> (B), D<sup>1</sup> (C) and D<sup>13</sup> (D) (quantization=64) with respect to MATV.

**Figure 5.** Distributions of HILAE (A) and ZP (B) (quantization=64) with respect to MATV.

**Figure 6**. Absolute Spearman rank correlation with MATV for each TF (quantization=64), considering different ranges of increasing MATVs.

**Figure 7**. Kaplan-Meier curves using volume and heterogeneity for(A) 112 esophageal patients,(B-C) 101 NSCLC patients.